Revista espanola de cardiologia最新文献

Introduction and objectives

To evaluate the impact of dexmedetomidine impact on cardiac surgery-associated acute kidney injury (CSA-AKI), kidney function, and metabolic and oxidative stress in patients undergoing coronary artery bypass grafting with heart-lung machine support.

Methods

A randomized double-masked trial with 238 participants (50-75 years) undergoing coronary artery bypass grafting was conducted from January 2021 to December 2022. The participants were divided into Dex (n = 119) and NS (n = 119) groups. Dex was administered at 0.5 mcg/kg over 10 minutes, then 0.4 mcg/kg/h until the end of surgery; the NS group received equivalent saline. Blood and urine were sampled at various time points pre- and postsurgery. The primary outcome measure was the incidence of CSA-AKI, defined as the occurrence of AKI within 96 hours after surgery.

Results

The incidence of CSA-AKI was significantly lower in the Dex group than in the NS group (18.26% vs 32.46%; P = .014). Substantial increases were found in estimated glomerular filtration rate value at T4–T6 (P < .05) and urine volume 24 hours after surgery (P < .01). Marked decreases were found in serum creatinine level, blood glucose level at T1–T2 (P < .01), blood urea nitrogen level at T3–T6 (P < .01), free fatty acid level at T2–T3 (P < .01), and lactate level at T3–T4 (P < .01).

Conclusions

Dex reduces CSA-AKI, potentially by regulating metabolic disorders and reducing oxidative stress.

Registered with the Chinese Clinical Study Registry (No. ChiCTR2100051804).

Introduction and objectives

Limited data exist on the prognostic usefulness of transthoracic echocardiography preceding MitraClip for chronic primary mitral regurgitation (MR). We evaluated the predictive ability of transthoracic echocardiography in this setting.

Methods

A total of 410 patients (median age, 83 years, 60.7% males) were included in the study. The primary outcome was the 1-year composite of all-cause mortality or heart failure hospitalization. Secondary endpoints encompassed individual elements of the primary outcome, the persistence of significant functional impairment or above-moderate MR at 1 year, and above-mild MR at 1-month.

Results

The only parameter associated with the risk of the primary outcome was a ventricular end systolic diameter index of ≥ 2.1 cm/m2, corresponding to the cohort's 4 th quartile (HR, 2.44; 95%CI, 1.09-4.68; P = .022). Concurrently, higher left atrial volume index (LAVi) and a mid-diastolic medial-lateral mitral annular diameter (MAD) equal to or above the cohort's median of 32.2 mm were linked to a higher probability of death and heart failure hospitalization, respectively. LAVi of ≥ 60 mL/m2, above-mild mitral annular calcification, and above-moderate tricuspid regurgitation conferred higher odds of functional class III-IV or above-moderate MR persistence. All variables except LAVi and MAD, as well as indexed mid-diastolic medial-lateral MAD of ≥ 20.2 mm/m2 and mitral effective regurgitant orifice area of ≥ 0.40 cm2, were associated with greater-than-mild MR at 1 month.

Conclusions

Preprocedural increased indexed left heart dimensions, mainly left ventricular end-systolic diameter index, MAD, mitral annular calcification, mitral effective regurgitant orifice area, and tricuspid regurgitation mark a less favorable course post-MitraClip for chronic primary MR.

Introduction

Methods

Results

Conclusions

Introduction and objectives

Methods

Results

Conclusions